The UK National Institute for Health and Care Excellence (NICE) recently announced approval for AstraZeneca‘s sodium glucose co-transporter 2 (SGLT2) inhibitor Forxiga (dapagliflozin) for chronic kidney disease (CKD). GlobalData believes that NICE’s approval for use of Forxiga signifies the drug’s major advantage over existing treatments and in targeting reduced glomerular filtration rate (GFR) and all-cause death. As CKD’s pathophysiology is most often tracked through an analysis of GFR, Forxiga’s approval is significant, as it can potentially reduce pressure in the glomeruli of the kidney, thus protecting them from damage.

Forxiga will be offered as part of the best current treatment, used alongside angiotensin-converting enzymes (ACE) inhibitors and angiotensin receptor blockers (ARBs) for the management of CKD. It will not, however, be a treatment option for transplant patients. SGLT2 inhibitors are not expected to be in direct competition with other classes of drugs, as they will be used in combination with other drugs for the management of CKD, making the market share of other drugs unaffected by the increased presence of alternative agents.

Key opinion leaders (KOLs) interviewed by GlobalData have emphasised that there is a desperate need for studies that investigate morbidity, comorbidity and hospitalisation endpoints in patients with CKD stages II-IV. According to data from the Phase III DAPA-CKD trial, Forxiga, in combination with standard of care, specifically ACE inhibitors and ARBs, lowered the composite risk of worsening renal function by 39% compared to placebo (risk lowered by 5.3%, p<0.0001). In addition, there was a significant (31%) reduction in risk of death from any cause compared to placebo, and Forxiga’s safety and tolerability data were in line with its existing safety profile. This positive trial data supported Forxiga’s priority review, since it offers significant advances over available options and demonstrated better efficacy, thus preventing the risk of cardiovascular and renal death.

According to physicians surveyed by GlobalData, guidelines followed by nephrologists in the UK are those published by NICE and the KDIGO clinical practice guidelines. Present guidance suggests dapagliflozin will be made available in patients with broad kidney damage and protein leaking into their urine. This consist of patients with an estimated GFR of 25–75mL/min/1.73m².

Guidelines updates regarding the use of SGLT2 inhibitors for CKD are expected to be published in the coming weeks. KOLs have highlighted that while side effects are favourable, nephrologists are unfamiliar with this class of drugs and will require guidance on dosage and monitoring instructions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Tick here to opt out of curated industry news, reports, and event updates from Clinical Trials Arena.

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.